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Abstract
Palliative care has not been focused on noncancer yet. Amyotrophic lateral sclerosis (ALS) 
is a fatal, rapid progressive, and intractable neurodegenerative disease. Individuals with 
advanced ALS cannot perform activities of daily living by themselves, but their mental 
awareness remains clear. Individuals with ALS experience various pain soon after diag-
nosis, and a multidisciplinary team approach is needed because their pain can become 
complicated Caring for individuals with ALS needs to both start and end with palliative 
care in the physical, psychological, social, and spiritual aspects. The Japanese Ministry 
of Health, Labour and Welfare enacted the Principles of Policy for Rare and Intractable 
Diseases (nanbyo), which were the first set of such principles to be established in the 
world. This chapter describes the palliative care in Japan, from the perspectives of nurs-
ing and nanbyo measures. Also, three unique characteristics of ALS care in Japan are 
mentioned: the high level of disagreement between patients and family; the high rate of 
ventilator use compared with Western countries; and the low consumption of morphine. 
Healthcare practitioners need to apply the notion of the total pain to provide palliative 
care to individuals with ALS and acknowledge the challenges of providing timely symp-
tomatic management.
Keywords: ALS, palliative care, total pain, end-of-life care, family care, home care support 
system
1. Introduction
Amyotrophic lateral sclerosis is the most common degenerative disease of the motor neuron 
system. This disease is also known as Lou Gehrig’s disease. The symptoms and progression 
processes can be quite varied in different people.
© 2017 The Author(s). Licensee InTech. This chapt r is distributed under the terms of the Creative Comm s
Attribution L cense (http://creativecommons. /licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
1.1. Characteristics of amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis (ALS) is a devastating, neurodegenerative, and progres-
sive disease with no established treatment. ALS is characterized by muscle weakness and 
atrophy, and these affect the upper and lower limb movements, swallowing, speech, and 
respiratory function. However, bowel, bladder, and oculomotor function and sensation are 
spared. The cognitive and behavioral symptoms have also been described, although frank 
dementia is a rare occurrence [1]. Patients with ALS may die within 3–5 years after the 
onset of their first symptoms if they do not choose to live with a ventilator [1]. Bulbar onset 
type, increased age, and front temporal dementia (FTD) are prognostic factors for shorter 
survival [2]. The course of ALS is quite uncertain, and sudden death or unexpected death 
is often seen [3]. Therefore, healthcare providers should consider end-of-life care soon after 
the diagnosis [3].
1.2. Epidemiology of ALS in Japan
The number of those patients with ALS has increased remarkably. Figure 1 shows the num-
ber of patients with ALS who were certified as eligible for receiving medical financial aid in 
Japan for the treatment of a designated rare and intractable disease, which increased from 860 
individuals in 1979 to 9950 individuals in 2015 [4].
The incidence of ALS in the Japanese population is much lower than in the Caucasian popula-
tions of Europe and North America. The prevalence and incidence rates per 100,000 people 
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Figure 1. The number of ALS patients who are issued certificates in Japan for the treatment of rare and intractable 
disease between 1979 and 2015. Data are cited from Japan Intractable Disease Information Center [4].
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per year in Japan were 9.9 and 2.2, respectively, in 2013 [5]. The highest prevalence, as well as 
incidence, was evident in the group comprised of individuals in their 70s, and the ratio of men 
to women was approximately 1.5 [5].
The aspects of ALS have also changed. A single-facility retrospective study conducted in rural 
Japan reported the following findings [6]. The percentage of ALS patients whose onset type 
was bulbar increased from 14.2% (1978–1982) to 38.3% (2008–2012) over the 35-year period 
of the study. The percentage of ALS patients with dementia increased from 0% (1978–1982) 
to 20.2% (2008–2012). The percentage of patients whose age at onset was ≥ 70 years increased 
from 0% (1978–1982) to 38.2% (2008–2012).
2. Continuous loss and decision-making accompanied by the disease 
progression of the disease characteristic in individuals with ALS
Individuals with ALS suffer from decreasing function in their activities of daily living (ADL), 
such as immobility, respiratory insufficiency, speech difficulties, and swallowing difficulties. 
Poor ADL performance leads to care burden. Physical pain in individuals with ALS is not 
proportional to the severity of the disorder [7]. Psychological distress is great even in the early 
stage shortly after diagnosis [8]. The reactions of the patients and their family members at the 
time of diagnosis need to be shared with the hospital and community care staff in order to 
start providing adequate support. Individuals with ALS can develop a sense of security and 
suppress cumulative suffering if they feel that they are supported from an early stage.
Individuals with ALS cope with relentless loss in the disease progression stage. When disease 
progression is fast, the patient often loses additional bodily functions before his or her illness 
acceptance can catch up. The patient’s psychological state can be unstable due to the steady loss 
in physical function at a time when various difficult decisions (e.g., when and how to utilize 
social services and undergo medical treatment) must be made by the patient and his or her 
family [9].
2.1. Palliative care for ALS symptoms and pain
The symptomatic management should be provided in a timely manner in order to slow pro-
gression and optimize quality of life (QOL). It can be said that care for individuals with ALS 
starts and ends with palliative care. Symptoms of ALS which need palliative care include 
motor dysfunction, dyspnea, dysphagia and drooling, dysarthria, and pain. Other symp-
toms such as depression, anxiety, sleep disturbances, and nightmares must be addressed 
with specific pharmacological and no pharmacological approaches including a supportive 
psychotherapy, which is usually best administered as family therapy.
2.1.1. Motor dysfunction and palliative care
It causes mental distress that patients cannot perform ADL by themselves and need to be cared 
for by others. Individuals with ALS experience repeated falls as physical function deteriorates, 
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which forces wheelchair dependence and eventually progresses to a bedridden condition. Living 
with this deterioration and disturbance in one’s body image is also painful. These patients lose 
their jobs, and the opportunities for going out and socializing are inevitably reduced. The range 
of life naturally becomes narrower. Accordingly, motor dysfunction develops into a spiritual 
pain whereby individuals with ALS question the meaning of life, thereby exacerbating psycho-
logical and social distress [10].
Healthcare practitioners need to respect and focus on the residual abilities of the individu-
als with ALS—not the parts that they cannot do—and make the utmost use of what they can 
accomplish. It is important to find and devise a way of life with the individual with ALS and 
his or her family members that incorporates adequate assistive devices or utensils so that 
tasks can be performed by the individuals with ALS.
Although the people surrounding individuals with ALS tend to thoughtlessly reach out 
because of feelings of pity and kindness and prevention from danger situations, these actions 
can increase their mental distress of the individuals with ALS and reduce their self-esteem 
[10]. Technology development makes individuals with ALS do themselves by operating envi-
ronmental devices, as long as they have a part of the body that they can move slightly, such 
as the tip of their little finger or eye tracking.
Human value is not changed at all even if the body cannot completely move. It is important 
for individuals with ALS to have roles and feel that he or she is needed from their surround-
ing friends and family. The healthcare profession needs to build up partnerships with their 
patients and their family members in order to enhance their autonomy and power to live.
In addition, active and passive physiotherapy has a pivotal role, especially in order to pre-
vent muscle contractures and joint stiffness, whereas acetylcholinesterase inhibitors (e.g., pyr-
idostigmine) may lead to a short-term improvement in muscle strength, especially during the 
early stages of the disease and in those with bulbar symptoms.
2.1.2. Respiratory dysfunction and palliative care
If breathing cannot be adequately performed, this will directly lead to a life crisis. Patients 
express the respiratory disorder caused by ALS as “feeling [like I am] drowning in the sea 
while in the land,” “feeling [like I am] being strangled with cotton,” and “suffering [because I] 
cannot cough up phlegm.” The leading cause of death of individuals with ALS is respiratory 
failure, and they must live with the fear of approaching death all the time.
For the early detection of respiratory disorders in homecare, healthcare practitioners need to 
perform peripheral oxygen saturation (SpO2) checkups during the nighttime and measure 
sniff nasal inspiratory pressure, the difference between chest girth at expiration and inspi-
ration, and forced vital capacity. Symptomatic treatments such as respiratory rehabilitation, 
mechanical insufflation-exsufflation (MI-E), noninvasive positive pressure ventilation (NPPV), 
tracheostomy, and tracheostomy positive pressure ventilation (TPPV) can also be applied.
Ideally, NPPV should be introduced before the respiratory muscles are excessively exhausted. 
However, some patients do not undergo the early introduction of NPPV because they believe 
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that they “do not want to live by relying on any machine” or “if [they] rely on machines, 
[their bodies will get] stuck.” In addition, sometimes the NPPV therapy itself is only trouble-
some when they are not well aware of respiratory insufficiency and cannot realize the effect 
of NPPV.
Healthcare practitioners need to explain how symptoms can be relieved, rather than just pro-
long life, in order to promote a better adaptation and tolerance to NPPV. Individuals with 
ALS are not able to detach and attach the NPPV mask whenever they desire due to upper limb 
disorders. Since displacement of the mask can cause death, [3], a sufficient home care support 
system must be prepared for each NPPV user.
Also, a small amount of morphine provides effective relief for respiratory distress in patients 
with ALS [11]. Morphine consumption in Japan is lower than in other countries. According to 
2008–2010 data compiled by the Ministry of Health, Labour and Welfare, morphine consump-
tion was 204.5 g/day per 1 million persons in the United States, 191.8 g/day per 1 million per-
sons in Canada, and only 7.2 g/day per 1 million persons in Japan [12]. The use of morphine 
for neurological diseases was approved by the Japanese national health insurance system in 
2011 [13]. Morphine consumption can be expected to increase in the near future.
2.1.3. Difficulty in swallowing and eating and palliative care
Oral intake can become difficult as ALS progresses. Poor oral intake or dysphagia as well 
as difficulty with self-feeding and meal preparation leads to weight loss and malnutrition 
and increases the risks of aspiration pneumonia and suffocation. Moreover, poor oral intake 
deprives the pleasure of individuals with ALS and lowers QOL. The long time required for 
oral ingestion leads to fatigue. Malnutrition causes not only respiratory waste but also the loss 
of spirit need to think or redesign the way of future life [14].
There are many ways to increase oral intake: consider the position of the neck and head, 
change the patient’s body posture, modify the type of food, use a thickener, conduct swallow-
ing rehabilitation therapies, perform an esophageal laryngectomy or total laryngectomy, etc. 
It is also important to collaborate with professionals such as speech therapists, dentists, and 
certified nurses who specialize in dysphagia. Percutaneous endoscopic gastrostomy place-
ment is also indicated.
2.1.4. Difficulty in speech and palliative care
Due to the disease progression, individuals with ALS are difficult to say what they want to 
say. The individuals with ALS frustrate that the things they want to convey do not pass well 
and experiences a sad feeling by being told that “I do not know what you are talking about” 
from others. Individuals with ALS may lose their voice by tracheostomy.
Communication greatly affects QOL of the individuals and their family. In recent years, 
remarkable progress has been made in the field of augmentative and alternative communica-
tion (AAC), which includes all forms of communication (other than oral speech) that are used 
to express thoughts, needs, wants, and ideas. Consequently, various communication devices 
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and switches are available. In cooperation with speech therapists and occupational therapists, 
selection and contrivance of a communication device is required along with aggravation of 
the disease condition.
As training and time are necessary to use communication devices, it is desirable to introduce 
them at an early stage where the disease state is mild, but until patients do not realize the 
necessity, they are reluctant to introduce. It is an important key whether or not the individuals 
with ALS desire to convey their thoughts and whether or not their family and supporters feel 
like wanting to hear the individual’s thoughts.
2.1.5. Physical pain
The two types of physical pain are summarized in Table 1. Although fasciculation—arising 
through degeneration of the intramuscular motor axons—and subsequent painful muscle 
cramps are often the first symptoms of the disease, the secondary in nature is most reported 
types of pain [15].
2.1.6. Total pain
As mentioned above, deterioration of physical function and various types of physical pain 
cause mental, social, and spiritual distress. These pains become increasingly complicated and 
cumulatively expand with disease progression. Therefore, the concept of “total pain” coined by 
Primary forms of pain
• Neuropathic pain (extremities)
• Painful cramps (lower limbs, hands, abdomen)
• Spasticity (lower limbs)
• Pain caused by inability to move and change position (diffuse, including buttocks, limbs, and trunk)
• Paresis of limbs (shoulder pain, articular pain)
• Joint contractures (hand and ankle joints)
• Itch (diffuse)
Secondary nature (most reported types of pain)
• Neck pain due to hyposthenia of neck muscles
• Back pain due to reduced mobility
• Pressure sores due to reduced mobility
• Pain due to suctioning of phlegm
• Articular pain due to reduced mobility
• Shoulder pain due to reduced mobility
• Facial pressure ulcers due to NIV mask
• Pain due to ventilator hose pulling or weighing
Table 1. Types of pain in individuals with ALS, adapted from Chió et al. [15].
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Dame Cicely Saunders to manage the cancer pain—which has physical, psychological, social, 
and spiritual components whereas the contribution of each component will be specific to each 
individual and his or her situation [16]—can also be applied to rare and intractable diseases 
[9, 13]. Pain will never be relieved by only paying attention to physical aspect (Figure 2). That 
is why individuals with ALS should be supported using a multidisciplinary team approach.
3. Government measurements in Japan
3.1. Definition of “Nanbyo”
Rare and intractable diseases are called nanbyo in Japan. Nanbyo is defined by the following 
four conditions: (1) no known cause, (2) no clearly established treatment, (3) rare disease sta-
tus, and (4) long-term care is typically required [4]. Nanbyo is the administrative term that the 
government uses to promote clinical investigations and research in order to establish effective 
treatments and improve cares [4]. Patients are often shocked by the poor image of the term 
nanbyo. However, they should understand the term in a positive sense. Nanbyo is the admin-
istrative term which has the meaning that the Japanese national government strengthens to 
clarify the causes of disease and effective treatments.
Patients registered as having one of the designated Nanbyo or the designated rare and intrac-
table diseases are eligible to participate in a subsidy scheme that covers medical expenses. The 
designated Nanbyo selected from rare and intractable diseases that meet the following two 
conditions: (1) diseases with a prevalence of less than 0.1% of the population in Japan (i.e., 
affecting less than approximately 140,000 persons) and (2) diseases with established objective 
diagnostic criteria. As of April 2017, 330 rare and intractable diseases were designated [4]. 
The typical neuromuscular nanbyo includes ALS, multisystem atrophy, Parkinson’s disease, 
spinocerebellar disease, and multiple sclerosis.
3.2. Historical development of Japan’s governmental policy
The system of rare and intractable diseases in Japan was started ahead of the world as 
“nanbyo measures” and gradually getting improved [17]. In 1972, the Ministry of Health, 
Figure 2. Total pain, adapted from Ushikubo [9].
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Labour and Welfare enacted the Principles of Policy for Rare and Intractable Diseases [4] 
which was the first set of principles to be enacted in the world. Since then, the government 
has promoted research and expanded support for individuals with rare and intractable 
diseases. At first, there were three pillars that were used to clarify causes and treatments: 
promoting surveys and research; establishing medical institutions; and reducing copay-
ments for medical fees.
In 1995, the Principles of Policy for Rare and Intractable Diseases was revised to include an 
additional two pillars: improving cooperation between community-based healthcare, medical, 
and welfare agencies; and promoting welfare measures aimed at improving QOL [4].
The characteristic of nanbyo is disease progression, while disability is defined as fixed disor-
ders. Individuals with nanbyo had not been recognized as the disabled based on the Act of 
Services and Supports for Persons with Disabilities. Since this Act was amended in 2013, indi-
viduals with nanbyo patients have been recognized as the disabled [18]. As a result, the use of 
disability welfare services (e.g., support consultations, prosthetic devices, and community life 
support projects) has been expanded to individuals with nanbyo.
According to the increasing number of people with intractable diseases, the budget required 
for medical expense subsidies has also expanded. In addition, from the viewpoint of fair-
ness, there was a demand for the further expansion and review of medical expense subsidies 
for people with other diseases which had not been defined as the designated nanbyo. More 
than 40 years have elapsed since the establishment of the Principles of Policy for Intractable 
Disease, and the “law concerning medicine etc. of intractable patients (nanbyo law)” [19] has 
been enforced since January 2015. This nanbyo law made stabilized medical expense subsidies 
by allocating financial resources such as a consumption tax [18, 19]. In addition, the des-
ignated nanbyo (i.e., the targeted diseases eligible for medical expenses subsidies) has been 
expanded from 56 diseases to 330 [17].
3.3. Social services
Public social services—which nanbyo patients can utilize—are gradually increasing. Individuals 
with nanbyo are available to utilize public social services by combining the following four sys-
tems: medical insurance, long-term care insurance, the welfare system for persons with dis-
abilities, and the nanbyo medical system. Since the different offices deal with each system, it 
is not easy to use them. However, these four systems are very proud of in the world by the 
fulfilling contents [19].
Even if healthcare practitioners encourage individuals with nanbyo to use social resources, 
they may be reluctant to initially propose the use of social resources. Multiple factors are 
implicated in the uptake of social services [20]. ‘Internal’ issues focused on retaining control 
and normality within the home. Suggesting an individual use social services can be perceived 
as insulting because it indicates that the individual cannot provide his or her own medical 
care good enough or family care is insufficient. Healthcare practitioners must consider the 
patient’s and family’s feelings whenever suggesting the use of social services and should 
research reasonable methods for proposing the use of services.
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4. Home care support system for individuals with ALS
Figure 3 shows the system for providing home care support during the early stage following 
diagnosis; Figure 4 shows the system used during the late and severe stages. The types and 
frequencies of use for various social services should be considered along with both disease 
aggravation and the preferences of the individual with ALS and his or her family.
Collaboration among multidisciplinary professionals is extremely important. Because nurses 
specialize in both medicine and care, they play the role of the glue that holds together the 
multidisciplinary team [21].
The concept of hope is important to supporting individuals with ALS. Healthcare practitio-
ners need to seek and sustain their hope in individuals with ALS. Individuals with ALS have 
hope for a cure, social support, searching for information, spiritual beliefs, limiting the impact 
of the disease, adapting to changing abilities, and self-transcendence [22].
Figure 3. Support system for individuals with early stage ALS.
Figure 4. Social services and home care support system for the individuals with ALS during disease progression.
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5. Timely decision-making for medical treatment
Although there is no effective cure for ALS, symptomatic treatment can improve QOL if it is 
provided in a timely manner. Also, the healthcare provider can modify the illness trajectory, 
hinder disease progression, and extend survival time. Providing symptomatic treatment is 
essential in order to gain the patient’s understanding and consent. Healthcare practitioners 
need to understand the reasons why psychological distress of individuals with ALS is gener-
ated by social interaction.
Individuals with ALS can hardly accept their diagnosis. As ALS rapidly progresses, their ill-
ness acceptance cannot catch up with the reality of disease condition. It is no wonder that 
patients expect to return their previous health and become well someday, while healthcare 
practitioners play the percentages based on their knowledge of the disease characteristics. 
Individuals with ALS suffer from this gap between them and their healthcare practitioners. 
Also, their families have the poor understanding of the reality of disease progression. This 
also allows increasing the suffering of the individuals with ALS [23].
Providing information is an important part of decision-making support during disease pro-
gression. Healthcare providers consider timing to be a key point in the decision-making pro-
cess and often postpone decisions until it is not too late.
6. End-of-life care in Japan
6.1. Two terminal points in individuals with ALS
Individuals with ALS have two terminal points. As respiratory failure worsens, if the 
patient decides not to receive TPPV, then he or she will die at this primary terminal point. If 
an individual with ALS selects to receive TPPV at this primary terminal point, he or she will 
encounter the secondary terminal point at time that TPPV can no longer provide respiratory 
management.
Ten-year survival rate was 87.1% among individuals with ALS who underwent TPPV 
from 2000 to 2007 [24]. TPPV allows long-term survival for individuals with ALS, but 
patients with terminal cancer are limited to live longer even if TPPV is initiated. The 
other difference between cancer and ALS, as shown in Figure 5, is that ALS is living with 
fear of dying all the time, while cancer patient can change the gear from living positive 
to death.
6.2. Rates of TPPV use
The rate of use of TPPV is higher in Japan than Western countries, as shown in Table 2. Some 
reasons for this discrepancy are summarized in Table 3.
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ALS ࣭Relentless disease progression from onset
࣭Never feeling of recuperaon
࣭Living and dying always at the same time
Cancer ࣭Gear change from positive living to preparaon for dying
onset death
onset death
Recurrence
Living
Living
Dying
Dying
Figure 5. Difference between ALS and cancer.
Citation, which data were 
requoted
Country Rate (%) Study method
Furukawa et al. [25] Japan 29.30% National study
Western countries 1.5–3.2%
Tagami et al. [26] Japan and Asian 
countries
12.7–21%
Britain 0% A British series of 50 patients
Germany 3%
USA 1.4–14%
Canada 1.50%
France 2.5–5%
Norway 7% for males and 3.8%  
for females
Italy 10.60% The largest study in north 
Italy from 1995 to 2004
Denmark 22%
Rabkin et al. [27] USA 2–6%
Europe 0–10.6%
Japan 25–46%
Lee et al. [28] Taiwan 20.97%
Table 2. International comparison of TPPV rates.
Palliative Care in Japan for Individuals with Amyotrophic Lateral Sclerosis
http://dx.doi.org/10.5772/intechopen.69773
101
6.3. High level of disagreement between individuals with ALS and their family members 
in Japan
Differing opinions about the use of TPPV are often seen between individuals with ALS and 
their family members. Fifty-four percent of Japanese patients oppose TPPV compared with 
10% of Japanese caregivers, but American patients and caregivers show greater agreement in 
decision-making than their Japanese counterparts [30].
There is no correct answer regarding decision-making. The most important thing on decision-
making is what the individual with ALS thinks. However, Japanese individuals with ALS 
consider the burden of care on their family members to be greater than the burden on them-
selves and often do not want to receive TPPV. Families want individuals with ALS to receive 
TPPV because they want their loved ones to live as long as possible. This relationship, which 
considers each other, results in a large amount of disagreement between the individuals with 
ALS and their family members.
Having sufficient time to think and discuss will lead to the best decision-making. Healthcare 
professionals need to promote individuals with ALS discussing decision-making with the 
relevant family members [31]. Early intervention is necessary before the speech difficulties 
Citation Reasons
Tagami et al. [26] 1. Attributed to religious, ethnic, and cultural differences
2. Financial considerations: the Japanese government covers all 
costs for noninvasive/invasive mechanical ventilation at any age 
for both inpatients and outpatients
3. Regular follow-up examinations at the same institute due to 
increased availability of continue services and improved knowl-
edge and education regarding ALS
4. Peer counseling by the Japanese ALS Association (JALSA)
5. Implementation of the long-term care insurance (LTCI) as a new 
and fundamentally reformed social insurance system at 2000 in 
Japan
Rabkin et al.[27] Different conceptualizations of the physician’s role in medical 
decision-making, attitudinal differences among patients, caregivers 
and healthcare professionals and
Vianello et al. [29] 1. To underline a proactive approach by Japanese physicians 
toward TV
2. Traditional fiduciary relationship that exists between the patient 
and the physician (the traditional Japanese paternalistic medical 
ethos dictating that “the doctor knows best” associated with 
physician’s belief that patient well-being is the most)
3. Be attributable to the contribution offered by family members, 
given that the family’s obligations as home care providers during 
sickness are deeply embedded in
Table 3. Reasons why Japan has a higher rate of TPPV use than other countries.
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associated with ALS become severe [30]. A study on American and Canadian patients with 
ALS reported that advanced directives were in place for 88.9% of patients and followed 
for 96.8% of patients [32]. However, advanced directives have not been familiarized yet in 
Japan [33].
Reference Published Year Country Method Place of death
Gil et al. [35] 2008 France •  302 patients in one of 
the 16 ALS centers in 
15 French regions
63% of patients died in a 
medical facility
•  Prospective 
investigation
Yang et al. [36] 2011 China •  139 patients in West 
China Hospital of 
Sichuan Univ.
82% of patients died at 
home
•  Survey to family 
members, caregivers, 
family physicians
Spataro et al. [37] 2010 Italy •  182 patients in a 
single ALS tertiary 
center
85.2% of patients died 
at home
•  Consultation with 
relatives or family 
physicians
Ushikubo [38] 2015 Japan •  14 patients in users of 
home care nursing
43% of patients died at 
home
•  Interview survey with 
home care nurses
Dominguez-Berjon 
et al. [39]
2015 Spain •  1035 in the 
Autonomous 
Community of 
Madrid
56.1% died in a hospital
•  A population-based 
cross-sectional study
30.4% at home, 8.3% in a 
residential home
5.1% unknown
Escarrabill et al. [41] 2014 Portuguese •  77 from five hospitals 57% of patients died in 
a home
•  A retrospective 
medical records 
analysis
Tsai et al. [42] 2013 Taiwan •  751 from the National 
Health Insurance 
Research Database
53.5% died in a medical 
facility
•  A retrospective 
population-based 
study
Table 4. International comparison of the places of death of individuals with ALS.
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6.4. End-of-life care for patients with ALS receiving NPPV
It is true that palliative end-of-life care for individuals with ALS has not progressed much 
in Japan [33, 34]. People who use NPPV are increasing because it is a way to palliate respi-
ratory deficiency and give time for decision-making on TPPV. Euthanasia is not legally 
permitted in Japan. However, NPPV cannot palliate respiratory failure if the disease is 
severely aggravated [35]. Palliative end-of-life care for patients who choose to remain on 
NPPV as the ceiling of medical treatment for respiratory failure has received little focus. 
The development of palliative end-of-life care for ALS patients receiving NPPV is needed 
[35].
6.5. Place of death among individuals with ALS
Understanding the causes and places of death of ALS patients is necessary to develop bet-
ter end-of-life care. There are seven articles [36–42] that clarify the causes and places of 
death. The primary cause of death remains respiratory failure. The secondary causes of 
death vary and include sudden death, death during sleep [38], nutritional causes [37], and 
cardiovascular diseases [42]. Table 4 summarizes seven articles on the places of death of 
individuals with ALS, and these also vary. Age, marital status, and the socioeconomic level 
of the patient also influence the places of death of patients with ALS [40]. Further research 
is necessary to develop end-of-life care by elucidating the dying process and analyzing the 
place of death.
7. Conclusion
There is no effective cure for ALS, but symptomatic treatment accomplishes the purpose of 
palliative care, extends the patient’s survival time, and improves their QOL. Healthcare prac-
titioners have many ways to improve illness trajectory and QOL by coping with the various 
symptoms caused by disease progression in a timely manner. It is important to provide men-
tal care, decision-making support, and family support via multidisciplinary collaboration. 
Healthcare practitioners make an effort to cherish hope and support the autonomy of the indi-
viduals with ALS and their family members. Moreover, it challenges to develop and provide 
palliative care on the terminal withdrawal of NPPV.
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